From 2013 to 2022, the rate of asthma-related hospitalizations that led to ICU admission did not change in adults but rose in children/adolescents, according to data published in Annals of the American Thoracic Society.
“Despite significant advances in asthma treatment over the last decade, hospital admission rates and admissions requiring ICU have not decreased,” Jacob McCoy, MD, asthma fellow at The Hospital for Sick Children, and colleagues wrote.
Using 2013 to 2022 data from population-based health administrative databases, McCoy and colleagues evaluated 52,919 individuals aged 0 to 59

The FDA has approved Lisraya for the treatment of dermatomyositis in adults, the agency announced in a press release.
The approval makes brepocitinib (Lisraya, Priovant Therapeutics) the first oral drug indicated for dermatomyositis.
“For too long, patients with dermatomyositis have faced a significant unmet need for effective treatments, often relying on therapies meant for other diseases,” Nikolay Nikolov, MD, director of the office of immunology and inflammation in the FDA’s Center for Drug Evaluation and Research, said in the release. “Today’s approval is a meaningful step forward, giving

The FDA has approved tirzepatide for reduction of cardiovascular risk in adults with type 2 diabetes, Eli Lilly announced.
Tirzepatide (Mounjaro), a dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, was already approved for improvement of glucose levels in patients with diabetes aged at least 10 years, and now has an indication for lowering risk for major adverse CV events, including CV death, nonfatal myocardial infarction and nonfatal stroke, in adults with diabetes at high risk for them, according to a company press release.
The approval was based on data from

Electric bikes — or e-bikes — have become a popular mode of transportation in the United States, with the American College of Surgeons citing the sale of more than 1.1 million e-bikes in 2022 and a projected annual growth rate of 10%.
But with the increased use of e-bikes comes an increased risk for injury. A study published in 2025 by Brian R. Waterman, MD, FAAOS, and colleagues showed a total of 45,845 nationally estimated e-bike-related injuries occurred between 2013 and 2022, with a 90.9% increase in the frequency of injuries from 2019 to 2022.
“There is definitely an exponential rise in

DENVER — Across four IOLs, a refractive extended depth of focus lens demonstrated the strongest natural distance image quality, followed by a full visual range IOL, according to a study.
Modulation transfer function (MTF) measurements and more complex metrics based on MTF, including the area under the MTF (MTFa), are commonly used to evaluate distance image quality for IOLs. However, visual acuity outcomes obtained in a clinical setting may not always be an indicator of quality of vision in more natural conditions, Aixa Alarcon, PhD, of Johnson & Johnson Vision, told Healio at the

E-scooters are popular for recreation and transportation, with ride-share options available in 133 cities across the United States and sales expected to increase from 1.44 million in 2025 to 2.39 million by 2031.
But traumatic brain injuries accounted for approximately 36 of every 100 moderate-to-severe e-scooter injuries in the National Major Trauma Registry for England and Wales between 2020 and 2022, according to data published in Scientific Reports.
Also, risks for traumatic brain injury were more common among e-scooter riders compared with riders of motorcycles (RR = 3.45; 95% CI,

The federal government’s dialysis expenditures may be impacted by the Medicare Secondary Payer Act, according to study data published in the Journal of the American Society of Nephrology.
The Medicare Secondary Payer Act, originally enacted in 1980 and extended to end-stage kidney disease in 1981, with the coordination period lengthened to its current 30 months in 1997, established employer group health plans as the primary insurance payer for patients with end-stage kidney disease with Medicare as a secondary payer for 30 months; after that period, Medicare would become the primary payer,

Transgender adolescents who have bone mineral density declines during pubertal suppression regain BMD after gender-affirming hormone therapy, according to findings published in JAMA Pediatrics.
In a systematic review and meta-analysis of 10 longitudinal observational studies, researchers found that BMD rebounded for transgender adolescents after they initiated gender-affirming HT, though BMD z scores at the lumbar spine remained below baseline values.
“This means that we cannot yet determine whether skeletal recovery ultimately becomes complete over the longer term,” Daniele Tienforti, MD,

Discontinuing chronic daily therapies while taking cystic fibrosis triple therapy did not result in greater lung function reduction or a higher probability of exacerbations, according to study findings.
These data were published in Annals of the American Thoracic Society.
“Treatment simplification has become a legitimate part of the conversation in the era of highly effective CFTR modulators,” Cynthia D. Brown, MD, professor of clinical medicine and adult cystic fibrosis director at Indiana University School of Medicine, told Healio. “Our findings provide additional evidence that some chronic

Genetic ancestry may have significant associations with colorectal cancer incidence and age-specific risk.
An evaluation of more than 300,000 individuals with whole genome sequencing showed that individuals with European ancestry had greater overall odds of developing colorectal cancer, but other lineages, including American admixed-Latino and East Asian, had higher risk for disease at younger ages.
“It’s important to look at genetic ancestry rather than simply race or ethnicity alone,” Timothy M. Pawlik, MD, MPH, PhD, chair of the department of surgery and Urban Meyer III and Shelley Meyer